Keyphrases
Malignant Pleural Mesothelioma
100%
Progression-free Survival
100%
Cisplatin
100%
Vinorelbine
100%
ERCC1
100%
Immunohistochemistry
20%
Long Progression-free Survival
13%
Immunoreaction
6%
Multivariate Cox Regression
6%
Diagnostic Biopsy
6%
Tumor Samples
6%
Tumor Tissue
6%
Formalin-fixed Paraffin-embedded Tissue
6%
Inoperable Patients
6%
Score-based
6%
Phase II Clinical Trial
6%
Hazard Ratio
6%
Thoracic Diseases
6%
Confidence Interval
6%
Positive Groups
6%
Overall Survival
6%
Time to Progression
6%
Staining Intensity
6%
Non-neoplastic
6%
Median Progression-free Survival
6%
Patient Demographics
6%
Tumor
6%
Tumor Cells
6%
Combination Therapy
6%
Medicine and Dentistry
Progression Free Survival
100%
Vinorelbine
100%
Base Excision Repair
100%
Cisplatin
100%
Neoplasm
20%
Immunohistochemistry
20%
Population Research
6%
Hazard Ratio
6%
Proportional Hazards Model
6%
Biopsy Technique
6%
Overall Survival
6%
Clinical Trial
6%
Tumor Cell
6%
Diagnosis
6%
Patient Population
6%
Formaldehyde
6%
Combination Therapy
6%
Retrospective Study
6%
Pharmacology, Toxicology and Pharmaceutical Science
Progression Free Survival
100%
Pleura Mesothelioma
100%
Cisplatin
100%
Neoplasm
80%
Formaldehyde
20%
Combination Therapy
20%
Overall Survival
20%
Retrospective Study
20%
Population Study
20%
Clinical Trial
20%
Biochemistry, Genetics and Molecular Biology
Cisplatin
100%
Base Excision Repair
100%
Progression Free Survival
100%
Population Research
6%
Retrospective Study
6%
Overall Survival
6%
Clinical Trial
6%
Immunology and Microbiology
Progression Free Survival
100%
Excision Repair
100%
Tumor Cell
6%
Overall Survival
6%
Population Research
6%